Top

Clinical Reviews in Allergy & Immunology

Published in:

18-01-2022 | Systemic Lupus Erythematosus

Anti-Ro52 Autoantibody Is Common in Systemic Autoimmune Rheumatic Diseases and Correlating with Worse Outcome when Associated with interstitial lung disease in Systemic Sclerosis and Autoimmune Myositis

Author: Edward K. L. Chan

Published in: Clinical Reviews in Allergy & Immunology | Issue 2/2022

Abstract

This review highlights the 30 plus years research progress since the discovery of autoantibody to Ro52/TRIM21 in patients with systemic lupus erythematosus (SLE) and Sjögren’s syndrome (SjS). After the initial expression cloning of the Ro52 cDNA, it has taken many years to the current understanding in the interesting biological function of Ro52 as an E3 ubiquitin ligase and its role in innate immune clearance of intracellular IgG-bound complex. Early observations show that anti-Ro52, mostly associated with anti-SS-A/Ro60 and/or anti-SS-B/La, is commonly found in SLE (40–70%), SjS (70–90%), neonatal lupus erythematosus (NLE, 75–90%), and subacute cutaneous lupus erythematosus (50–60%). Anti-Ro52 has long been postulated to play a direct pathogenic role in congenital heart block in NLE as well as in the QT interval prolongation in some adults. The widespread availability of the anti-Ro52 assay has led to the detection of anti-Ro52 in other diseases including autoimmune hepatitis (20–40%), systemic sclerosis (10–30%), and autoimmune myositis (20–40%). More than ten studies have pointed to an association of anti-Ro52 with interstitial lung disease and, more importantly, correlating with poor outcome and worse survival. Other studies are implicating an interesting role for anti-Ro52 in the diagnosis of certain cancers. Future studies are needed to examine the mechanism in the pathogenesis of anti-Ro52 and carefully documenting its causal relationships in different disease conditions.

Lee AYS (2017) A review of the role and clinical utility of anti-Ro52/TRIM21 in systemic autoimmunity. Rheumatol Int 45(1):183–191

Oke V, Wahren-Herlenius M (2012) The immunobiology of Ro52 (TRIM21) in autoimmunity: a critical review. J Autoimmun 39(1–2):77–82CrossRef

Clark G, Reichlin M, Tomasi TB Jr (1969) Characterization of a soluble cytoplasmic antigen reactive with sera from patients with systemic lupus erythmatosus. J Immunol 102(1):117–122CrossRef

Tan EM, Kunkel HG (1966) Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus. J Immunol 96(3):464–471CrossRef

Alspaugh MA, Tan EM (1975) Antibodies to cellular antigens in Sjogren’s syndrome. J Clin Invest 55(5):1067–1073CrossRef

Alspaugh M, Maddison P (1979) Resolution of the identity of certain antigen-antibody systems in systemic lupus erythematosus and Sjogren’s syndrome: an interlaboratory collaboration. Arthritis Rheum 22(7):796–798CrossRef

Tan EM et al (1988) Antinuclear antibodies (ANAs): diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity. Clin Immunol Immunopathol 47(2):121–141CrossRef

Hendrick JP et al (1981) Ro small cytoplasmic ribonucleoproteins are a subclass of La ribonucleoproteins: further characterization of the Ro and La small ribonucleoproteins from uninfected mammalian cells. Mol Cell Biol 1(12):1138–1149

Wolin SL, Steitz JA (1984) The Ro small cytoplasmic ribonucleoproteins: identification of the antigenic protein and its binding site on the Ro RNAs. Proc Natl Acad Sci U S A 81(7):1996–2000CrossRef

10.

Ben-Chetrit E et al (1988) A 52-kD protein is a novel component of the SS-A/Ro antigenic particle. J Exp Med 167(5):1560–1571CrossRef

11.

Chan EKL, Buyon JP (1994) The SS-A/Ro antigen. In: Manual of Biological Markers of Disease. Springer, Dordrecht, Netherlands, Dordrecht, pp 402–431

12.

Buyon JP et al (1990) Effective separation of the 52 kDa SSA/Ro polypeptide from the 48 kDa SSB/La polypeptide by altering conditions of polyacrylamide gel electrophoresis. J Immunol Methods 129(2):207–210CrossRef

13.

Slobbe RL et al (1991) Detection and occurrence of the 60- and 52-kD Ro (SS-A) antigens and of autoantibodies against these proteins. Clin Exp Immunol 86(1):99–105CrossRef

14.

Chan EKL et al (1991) Molecular definition and sequence motifs of the 52-kD component of human SS-A/Ro autoantigen. J Clin Invest 87(1):68–76CrossRef

15.

Itoh K, Itoh Y, Frank MB (1991) Protein heterogeneity in the human Ro/SSA ribonucleoproteins. The 52- and 60-kD Ro/SSA autoantigens are encoded by separate genes. J Clin Invest 87(1):177–86

16.

Wang D et al (2001) Leucine zipper domain of 52 kDa SS-A/Ro promotes protein dimer formation and inhibits in vitro transcription activity. Biochim Biophys Acta 1568(2):155–161CrossRef

17.

Buyon JP et al (1989) Acquired congenital heart block. Pattern of maternal antibody response to biochemically defined antigens of the SSA/Ro-SSB/La system in neonatal lupus. J Clin Invest 84(2):627–34

18.

Ben-Chetrit E, Fox RI, Tan EM (1990) Dissociation of immune responses to the SS-A (Ro) 52-kd and 60-kd polypeptides in systemic lupus erythematosus and Sjogren’s syndrome. Arthritis Rheum 33(3):349–355CrossRef

19.

Ricchiuti V et al (1994) Epitope mapping with synthetic peptides of 52-kD SSA/Ro protein reveals heterogeneous antibody profiles in human autoimmune sera. Clin Exp Immunol 95(3):397–407CrossRef

20.

Langguth DM et al (2007) Specific testing for “isolated” anti-52 kDa SSA/Ro antibodies during standard anti-extractable nuclear antigen testing is of limited clinical value. J Clin Pathol 60(6):670–673CrossRef

21.

Menor Almagro R et al (2016) Association of anti-Ro52, anti-Ro60 and anti-La antibodies with diagnostic, clinical and laboratory features in a referral hospital in Jerez. Spain Reumatol Clin 12(5):256–262CrossRef

22.

Keech CL, Gordon TP, McCluskey J (1995) Cytoplasmic accumulation of the 52 kDa Ro/SS-A nuclear autoantigen in transfected cell lines. J Autoimmun 8(5):699–712CrossRef

23.

Schmitz M et al (1997) Characterization of murine monoclonal antibodies against the Ro52 autoantigen. Clin Exp Immunol 110(1):53–62CrossRef

24.

Salomonsson S et al (2004) Cloning and characterization of two human Ro52-specific monoclonal autoantibodies directed towards a domain associated with congenital heart block. J Autoimmun 22(2):167–177CrossRef

25.

Itoh Y et al (1992) Autoantibodies to the Ro/SSA autoantigen are conformation dependent. II: antibodies to the denatured form of 52 kD Ro/SSA are a cross reacting subset of antibodies to the native 60 kD Ro/SSA molecule. Autoimmunity 14(2):89–95

26.

Mahler M et al (2014) Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res 2014:315179

27.

Buyon JP et al (1994) Autoantibody responses to the “native” 52-kDa SS-A/Ro protein in neonatal lupus syndromes, systemic lupus erythematosus, and Sjogren’s syndrome. J Immunol 152(7):3675–3684CrossRef

28.

Clancy RM et al (2005) Maternal antibody responses to the 52-kd SSA/RO p200 peptide and the development of fetal conduction defects. Arthritis Rheum 52(10):3079–3086CrossRef

29.

Salomonsson S et al (2005) Ro/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block. J Exp Med 201(1):11–17CrossRef

30.

Gkoutzourelas A et al (2018) Anti-Ro60 seropositivity determines anti-Ro52 epitope mapping in patients with systemic sclerosis. Front Immunol 9:2835CrossRef

31.

Peene I et al (2002) Anti-Ro52 reactivity is an independent and additional serum marker in connective tissue disease. Ann Rheum Dis 61(10):929–933CrossRef

32.

Pourmand N, Pettersson I (1998) The Zn2+ binding domain of the human Ro 52 kDa protein is a target for conformation-dependent autoantibodies. J Autoimmun 11(1):11–17CrossRef

33.

Zachou K et al (2015) Anti-SLA/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis. Liver Int 35(2):660–672CrossRef

34.

Brito-Zeron P et al (2016) Autoimmune congenital heart block: complex and unusual situations. Lupus 25(2):116–128CrossRef

35.

Rhodes DA, Trowsdale J (2007) TRIM21 is a trimeric protein that binds IgG Fc via the B30.2 domain. Mol Immunol 44(9):2406–14

36.

Yang Y et al (1999) Protein-protein interactions between native Ro52 and immunoglobulin G heavy chain. Scand J Immunol 49(6):620–628CrossRef

37.

James LC et al (2007) Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function. Proc Natl Acad Sci U S A 104(15):6200–6205CrossRef

38.

Reymond A et al (2001) The tripartite motif family identifies cell compartments. EMBO J 20(9):2140–2151CrossRef

39.

Nisole S, Stoye JP, Saib A (2005) TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol 3(10):799–808CrossRef

40.

Espinosa A et al (2006) The Sjogren’s syndrome-associated autoantigen Ro52 is an E3 ligase that regulates proliferation and cell death. J Immunol 176(10):6277–6285CrossRef

41.

Wada K, Kamitani T (2006) Autoantigen Ro52 is an E3 ubiquitin ligase. Biochem Biophys Res Commun 339(1):415–421CrossRef

42.

Espinosa A et al (2009) Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway. J Exp Med 206(8):1661–1671CrossRef

43.

Mallery DL et al (2010) Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc Natl Acad Sci U S A 107(46):19985–19990CrossRef

44.

Watkinson RE, McEwan WA, James LC (2014) Intracellular antibody immunity. J Clin Immunol 34 Suppl 1(9):S30–4

45.

Clift D et al (2017) A method for the acute and rapid degradation of endogenous proteins. Cell 171(7):1692–1706 e18

46.

McCauliffe DP et al (1994) Autoimmune sera react with multiple epitopes on recombinant 52 and 60 kDa Ro(SSA) proteins. J Rheumatol 21(6):1073–1080

47.

Schulte-Pelkum J, Fritzler M, Mahler M (2009) Latest update on the Ro/SS-A autoantibody system. Autoimmun Rev 8(7):632–637CrossRef

48.

Hervier B et al (2009) Clinical significance of anti-Ro/SSA-52 kDa antibodies: a retrospective monocentric study. Rheumatology (Oxford) 48(8):964–967CrossRef

49.

Guo YP et al (2014) The prevalence of antinuclear antibodies in the general population of china: a cross-sectional study. Curr Ther Res Clin Exp 76:116–119CrossRef

50.

Hardin JA (1986) The lupus autoantigens and the pathogenesis of systemic lupus erythematosus. Arthritis Rheum 29(4):457–460CrossRef

51.

Boire G et al (1995) Purification of antigenically intact Ro ribonucleoproteins; biochemical and immunological evidence that the 52-kD protein is not a Ro protein. Clin Exp Immunol 100(3):489–498CrossRef

52.

Tseng CE et al (1997) The 52-kd protein as a target of intermolecular spreading of the immune response to components of the SS-A/Ro-SS-B/La complex. Arthritis Rheum 40(5):936–944CrossRef

53.

Topfer F, Gordon T, McCluskey J (1995) Intra- and intermolecular spreading of autoimmunity involving the nuclear self-antigens La (SS-B) and Ro (SS-A). Proc Natl Acad Sci U S A 92(3):875–879CrossRef

54.

Kinoshita G et al (1998) Spreading of the immune response from 52 kDaRo and 60 kDaRo to calreticulin in experimental autoimmunity. Lupus 7(1):7–11CrossRef

55.

Keech CL, Gordon TP, McCluskey J (1996) The immune response to 52-kDa Ro and 60-kDa Ro is linked in experimental autoimmunity. J Immunol 157(8):3694–3699CrossRef

56.

Koenig M et al (2007) Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 9(4):R78CrossRef

57.

Venables PJ (1997) Antibodies to Jo-1 and Ro-52: why do they go together? Clin Exp Immunol 109(3):403–405CrossRef

58.

Buyon JP (1996) Neonatal lupus. Curr Opin Rheumatol 8(5):485–490CrossRef

59.

Buyon JP et al (1993) Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children. Comparison of enzyme-linked immunosorbent assay and immunoblot for measurement of anti-SS-A/Ro and anti-SS-B/La antibodies. Arthritis Rheum 36(9):1263–73

60.

Reichlin M et al (1994) Concentration of autoantibodies to native 60-kd Ro/SS-A and denatured 52-kd Ro/SS-A in eluates from the heart of a child who died with congenital complete heart block. Arthritis Rheum 37(11):1698–1703CrossRef

61.

Ghillani P et al (2011) Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study. Autoimmun Rev 10(9):509–513CrossRef

62.

Czaja AJ et al (1994) Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology 107(1):200–207CrossRef

63.

Parveen S et al (1998) Antibodies to Ro/La, Cenp-B, and snRNPs antigens in autoimmune hepatitis of North America versus Asia: patterns of immunofluorescence, ELISA reactivities, and HLA association. Dig Dis Sci 43(6):1322–1331CrossRef

64.

Montano-Loza AJ et al (2011) Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. Liver Int

65.

Eyraud V et al (2009) Significance of antibodies to soluble liver antigen/liver pancreas: a large French study. Liver Int 29(6):857–864CrossRef

66.

Granito A et al (2007) Antibodies to SS-A/Ro-52kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis. Aliment Pharmacol Ther 26(6):831–838CrossRef

67.

Targoff IN (1992) Autoantibodies in polymyositis. Rheum Dis Clin North Am 18(2):455–482CrossRef

68.

Satoh M et al (2017) A Comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol 52(1):1–19CrossRef

69.

Mahler M, Miller FW, Fritzler MJ (2014) Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev 13(4–5):367–371CrossRef

70.

Rutjes SA et al (1997) Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol 109(1):32–40CrossRef

71.

Dugar M et al (2010) Diagnostic utility of anti-Ro52 detection in systemic autoimmunity. Postgrad Med J 86(1012):79–82CrossRef

72.

Frank MB et al (1999) The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies. J Autoimmun 12(2):137–142CrossRef

73.

Brouwer R et al (2001) Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 60(2):116–123CrossRef

74.

Sabbagh S et al (2019) Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis 78(7):988–995CrossRef

75.

Chen F et al (2019) Clinical characteristics of dermatomyositis patients with isolated anti-Ro-52 antibody associated rapid progressive interstitial lung disease: data from the largest single Chinese center. Respir Med 155:127–132CrossRef

76.

Xing X, Li A, Li C (2020) Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis. Respir Med 172:106134

77.

Robbins A et al (2019) Diagnostic utility of separate anti-Ro60 and anti-Ro52/TRIM21 Antibody detection in autoimmune diseases. Front Immunol 10:444CrossRef

78.

Fujimoto M et al (1997) Prevalence and clinical relevance of 52-kDa and 60-kDa Ro/SS-A autoantibodies in Japanese patients with systemic sclerosis. Ann Rheum Dis 56(11):667–670CrossRef

79.

Parker JC, Burlingame RW, Bunn CC (2009) Prevalence of antibodies to Ro-52 in a serologically defined population of patients with systemic sclerosis. J Autoimmune Dis 6:2CrossRef

80.

Mierau R et al (2011) Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features. Arthritis Res Ther 13(5):R172CrossRef

81.

Hudson M et al (2012) Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. Arthritis Res Ther 14(2):R50CrossRef

82.

Wodkowski M et al (2015) Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival. Clin Exp Rheumatol 33(4 Suppl 91):S131–S135

83.

Goh NS et al (2008) Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 177(11):1248–1254CrossRef

84.

Johnson C et al (2016) Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease. Lung 194(5):733–737CrossRef

85.

La Corte R et al (2006) In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity 39(3):249–253CrossRef

86.

Vancsa A et al (2009) Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients. Rheumatol Int 29(9):989–994CrossRef

87.

Ferreira JP et al (2012) Anti-Ro52 antibodies and interstitial lung disease in connective tissue diseases excluding scleroderma. ISRN Rheumatol 2012:415272

88.

Marie I et al (2012) Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Semin Arthritis Rheum 41(6):890–899CrossRef

89.

Gunnarsson R et al (2016) Associations between anti-Ro52 antibodies and lung fibrosis in mixed connective tissue disease. Rheumatology (Oxford) 55(1):103–108CrossRef

90.

Reiseter S et al (2018) Progression and mortality of interstitial lung disease in mixed connective tissue disease: a long-term observational nationwide cohort study. Rheumatology (Oxford) 57(2):255–262CrossRef

91.

Bauhammer J et al (2016) Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: anti-Ro52 positivity as a marker for severity and treatment response. J Rheumatol 43(8):1566–1574CrossRef

92.

Shi J et al (2017) Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies. J Rheumatol 44(7):1051–1057CrossRef

93.

Sclafani A et al (2019) Presentations and outcomes of interstitial lung disease and the anti-Ro52 autoantibody. Respir Res 20(1):256CrossRef

94.

Lee A et al (2021) Anti-Ro52/TRIM21 is independently associated with pulmonary arterial hypertension and mortality in a cohort of systemic sclerosis patients. Scand J Rheumatol 1–6

95.

Kuboshima M et al (2006) Presence of serum tripartite motif-containing 21 antibodies in patients with esophageal squamous cell carcinoma. Cancer Sci 97(5):380–386CrossRef

96.

Lawley W et al (2000) Rapid lupus autoantigen relocalization and reactive oxygen species accumulation following ultraviolet irradiation of human keratinocytes. Rheumatology 39(3):253–261CrossRef

97.

Ohlsson M, Jonsson R, Brokstad KA (2002) Subcellular redistribution and surface exposure of the Ro52, Ro60 and La48 autoantigens during apoptosis in human ductal epithelial cells: a possible mechanism in the pathogenesis of Sjogren’s syndrome. Scand J Immunol 56(5):456–469CrossRef

98.

Wang J et al (2015) Plasma autoantibodies associated with basal-like breast cancers. Cancer Epidemiol Biomarkers Prev 24(9):1332–1340CrossRef

99.

Chatterjee M et al (2017) Utility of paraneoplastic antigens as biomarkers for surveillance and prediction of recurrence in ovarian cancer. Cancer Biomark 20(4):369–387CrossRef

100.

Hurley LC et al (2020) Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53. Cancer Biomark 27(3):407–421CrossRef

101.

Bogdanos DP et al (2021) Anti-Ro52 antibody is highly prevalent and a marker of better prognosis in patients with ovarian cancer. Clin Chim Acta 521:199–205CrossRef

102.

Eftekhari P et al (2000) Anti-SSA/Ro52 autoantibodies blocking the cardiac 5-HT4 serotoninergic receptor could explain neonatal lupus congenital heart block. Eur J Immunol 30(10):2782–2790CrossRef

103.

Boutjdir M et al (1997) Arrhythmogenicity of IgG and anti-52-kD SSA/Ro affinity-purified antibodies from mothers of children with congenital heart block. Circ Res 80(3):354–362CrossRef

104.

Lazzerini PE et al (2004) Prolongation of the corrected QT interval in adult patients with anti-Ro/SSA-positive connective tissue diseases. Arthritis Rheum 50(4):1248–1252CrossRef

105.

Yue Y et al (2015) Pathogenesis of the Novel Autoimmune-Associated Long-QT Syndrome. Circulation 132(4):230–240CrossRef

106.

Lazzerini PE et al (2021) Risk of QTc interval prolongation associated with circulating anti-Ro/SSA antibodies among US veterans: an observational cohort study. J Am Heart Assoc 10(4):e018735

107.

Szczerba BM et al (2016) Interaction between innate immunity and Ro52-induced antibody causes Sjogren’s syndrome-like disorder in mice. Ann Rheum Dis 75(3):617–622CrossRef

108.

Julkunen H et al (1993) Isolated congenital heart block. Long-term outcome of mothers and characterization of the immune response to SS-A/Ro and to SS-B/La. Arthritis Rheum 36(11):1588–98

109.

Salomonsson S et al (2002) A serologic marker for fetal risk of congenital heart block. Arthritis Rheum 46(5):1233–1241CrossRef

110.

Gordon P et al (2004) Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus. J Rheumatol 31(12):2480–2487

111.

Villalta D et al (2012) Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis. Autoimmun Rev 12(2):114–120CrossRef

Title: Anti-Ro52 Autoantibody Is Common in Systemic Autoimmune Rheumatic Diseases and Correlating with Worse Outcome when Associated with interstitial lung disease in Systemic Sclerosis and Autoimmune Myositis
Author: Edward K. L. Chan
Publication date: 18-01-2022
Publisher: Springer US
Keywords: Systemic Lupus Erythematosus
Systemic Sclerosis
Autoimmune Hepatitis
Mixed Connective Tissue Disease
Primary Biliary Cholangitis
Published in: Clinical Reviews in Allergy & Immunology / Issue 2/2022
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-021-08911-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2022

Autoantibodies in Neuropsychiatric Systemic Lupus Erythematosus (NPSLE): Can They Be Used as Biomarkers for the Differential Diagnosis of This Disease?

An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations

Autoantibody Markers of Increased Risk of Malignancy in Patients with Dermatomyositis

Serum ANCA as Disease Biomarkers: Clinical Implications Beyond Vasculitis

Antimitochondrial Antibodies: from Bench to Bedside

The Therapeutic Strategies for SLE by Targeting Anti-dsDNA Antibodies

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials